Publicacions en què col·labora amb Manuel Romero-Gómez (11)

2024

  1. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR–MASH score

    Liver International, Vol. 44, Núm. 1, pp. 202-213

2023

  1. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

2022

  1. Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology

    Liver International, Vol. 42, Núm. 8, pp. 1783-1792

2018

  1. Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression

    Journal of Gastroenterology and Hepatology (Australia), Vol. 33, Núm. 3, pp. 718-725

2015

  1. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

    World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174

  2. High efficacy and safety of triple therapy in hcv genotype 1 and moderate fibrosis: A multicenter study of clinical practice in Spain

    Annals of Hepatology, Vol. 14, Núm. 4, pp. 477-486

  3. Minimal Hepatic Encephalopathy and Critical Flicker Frequency Are Associated with Survival of Patients with Cirrhosis

    Gastroenterology, Vol. 149, Núm. 6, pp. 1483-1489

  4. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program

    Journal of Viral Hepatitis, Vol. 22, Núm. 5, pp. 469-480

2010

  1. Erratum: Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: Outcomes and factors predicting response (Am J Gastroenterol (2010) 105 (2164-2172) (DOI: 10.1038/ajg.2010.294)

    American Journal of Gastroenterology

  2. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: Outcomes and factors predicting response

    American Journal of Gastroenterology, Vol. 105, Núm. 10, pp. 2164-2172

  3. Serum metabolic signature of minimal hepatic encephalopathy by 1H-nuclear magnetic resonance

    Journal of Proteome Research, Vol. 9, Núm. 10, pp. 5180-5187